Biotech2 days ago
Haptena Therapeutics Launches with €3 Million Funding to Target KRAS-Mutated Tumors
Haptena Therapeutics, a biotech focused on KRAS-mutated tumors, launched operations and secured €3 million from Claris Ventures. Founded by Chiara Ambrogio and Roberto Chiarle, the company...